Differentiation-dependent expression of transgenes in engineered astrocyte cell lines

Area of Science:

• Neuroscience
• Molecular Biology
• Biotechnology

Background:

• Regulatable transgenes offer advanced research capabilities.
• Glial fibrillary acidic protein (GFAP) promoter is specifically expressed in astrocytes and upregulated by CNS injury.
• A GFAP promoter-driven system could enable responsive gene expression in the central nervous system (CNS).

Purpose of the Study:

• To assess the feasibility of using a human GFAP promoter fragment (gfa2) to drive regulatable transgene expression in rat C6 glioma cells.
• To investigate the potential of this system for astrocyte differentiation and gene therapy applications, including Parkinson's disease.

Main Methods:

• Stable transfection of C6 rat glioma cells with reporter (lacZ) and tyrosine hydroxylase (TH) transgenes driven by the gfa2 promoter.
• Treatment with forskolin to induce astrocyte-like differentiation and assess transgene response.
• Analysis of transgene mRNA and protein expression, and cell growth rates.

Main Results:

• The gfa2 promoter successfully drove transgene expression in C6 cells, responding to forskolin-induced differentiation.
• Tyrosine hydroxylase (TH) mRNA and protein levels were upregulated by forskolin in the TH-transgene cell line.
• Forskolin significantly inhibited C6 cell growth, suggesting potential for reduced tumor-forming capacity.

Conclusions:

• The gfa2 promoter is a viable tool for inducible transgene expression in astrocytes, responding to differentiation signals.
• This system holds potential for gene therapy of Parkinson's disease by enabling TH expression in CNS cells.
• Forskolin-induced differentiation and growth inhibition may enhance the utility of C6 cells in animal models.